Patents
Literature
3 results about "Amylin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Amylin, or islet amyloid polypeptide (IAPP), is a 37-residue peptide hormone. It is cosecreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1 (insulin:amylin). Amylin plays a role in glycemic regulation by slowing gastric emptying and promoting satiety, thereby preventing post-prandial spikes in blood glucose levels.
Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for incremental weight loss and management of adverse side effects of weight loss drugs on body composition
The present invention relates to methods for incremental weight loss and to the field of treatment to improve body composition changes and physical function with weight reduction. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), GIP, glucagon, amylin, or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.
Owner:VERU INC
Compounds for treatment of diabetes and related conditions
Compounds useful in the treatment or prevention of diabetes and related conditions and in the prevention, inhibition or reversal of amylin-amyloid fiber formation, the prevention of Langerhans island (beta) cell death, the prevention or reversal of the conversion of soluble human amylin to insoluble human amylin, the prevention and inhibition or reversal of cytotoxic amylin fiber formation. The present invention relates to compounds of formula (I): (I).
Owner:AUCKLAND UNISERVICES LTD +1
Modulators of calcitonin receptor and / or amylin receptor activity
The present application relates to compounds of Formula I, which modulate calcitonin receptor and / or amylin receptor activity and are useful in the treatment of bone, metabolic, cardiovascular, neurodegenerative and other disorders. I
Owner:ACONCAGUA BIOTECH